Jobs | Apartments |INDIAN ONLINE SHOP IN JAPAN
Home
COLORS OF INDIA

Worldwide>>>INDIA USA  Thu 12/12/2019 at 10:23 pm 
 

Health / Medical

.Top News |Economy |Today's Feature |Sports |INDO-JAPAN |Social |Travel |Business |Politics |Sciencetech |Fashion |Showbiz |Lifestyle |Medley |India Abroad |Health / Medical |Environment/Wildlife |Photo Feature |Video Coverage |TV & Media |Culture |Commentary |Religion |Crime & Corruption |Education |Defence |External |Security |Entertainment |Agriculture |Terrorism |Real Estate |Accident |Human Rights |Weather |Law & Administration |Extremism |Transport / Automobiles |Violence |Telecom |Food & Beverages |International |Insurgency |Literary |North Americas |South & East Asia |Middle East |Africas |Europe |South America |Central America |Oceania |Natural Calamity |ASSOCHAM News |Caribbean |Updates on the Indian Market |Direct Taxation (India) |Indirect Taxation (India) |Indian Corporate Law
New England Journal of Medicine publishes new analyses confirming that Sanofi Pasteur's Vaccine candidate safely protects pre-adolescents to adults against Dengue
29 July, 2015   COLORS OF INDIA NEWS AND MEDIA SERVICES






Lyon, France, July 28 (RDI IBNS) Sanofi Pasteur, the vaccines division of Sanofi, announced on Tuesday that new data analyses published in the New England Journal of Medicine (NEJM) provide a comprehensive picture of the potential public health impact of vaccinating endemic populations from pre-adolescence to adulthood against dengue.

Not only is this the largest population at risk of dengue globally, but individuals 9 years of age and older also represent a highly mobile group capable of spreading disease more broadly during outbreaks and also contributing substantially to the economic burden of dengue, for example in number of lost school and work days due to the disease. The NEJM article reported results from a new pooled efficacy analysis of individuals 9 years of age and older at vaccination from the two Phase III studies of Sanofi Pasteurs dengue vaccine. The new analysis documented that the vaccine protects two-thirds of these individuals (66%) against dengue, providing even greater protection against two clinically-relevant manifestations of dengue, namely severe dengue (93%) and prevention of hospitalizations due to dengue (80%) that account for the greatest human and economic burden of dengue in endemic countries. In addition, the dengue vaccine candidate protected volunteers 9 years of age and older who were previously exposed to dengue (82%), as well as those who were nave to dengue (52.5%) prior to vaccination. The clinical development program for the vaccine candidate includes studies with four-year, long-term follow-up phases, in line with WHO guidelines for dengue vaccine development. Results from first 25 months of the two Phase III efficacy studies were published in 2014.4,5 Interim data from the third year of these studies and interim data from the third and fourth years of the Phase II extension study in Thailand published in the new NEJM article confirm the continuing reduction of hospitalized dengue in the vaccinated population 9 years of age and older. The third-year interim data from the Asian Phase III study identified the need for further long-term surveillance in children under 9 years of age to assess the impact of the dengue vaccine candidate in these younger children. It is not unusual to require additional data on a new vaccine to determine its value in a specific age group, particularly young children, whose immune response to the vaccine and the disease itself may differ significantly from that of older children and adults, said Tim Endy, MD., MPH, Upstate University Hospital, New York. Endy said, It is reassuring to have confirmation of the safe protection that this vaccine offers against dengue in the endemic preadolescent to adult population, particularly coupled with its consistent efficacy and safety profile reported last year from the PIII studies across diverse geographic regions, ethnic study populations and dengue epidemiology covered. Maria Rosario Capeding from the Research Institute for Tropical Medicine in the Philippines, who is a lead author on the NEJM article, points out the potential public health benefit of having a first dengue vaccine available to protect individuals 9 years of age and older. This large, at-risk population includes the most dynamic members of the community who have the potential to spread disease widely and also contribute most to dengues heavy societal impact in terms of school absences and lost work productivity. Certainly, individuals 9 years of age and older represent a compelling target group for an immunization program against dengue aimed at significantly reducing overall disease burden, Capeding said.

For any concern and query about the news email to readers@rangdeindia.jp



Rangdeindia.jp contains copyrighted material, trademarks and other proprietary information, including, but not limited to, text, software, photos, video, graphics, music and sound, and the entire contents of Rangdeindia.jp are copyrighted as a collective work under the Indian Copyright Act. Rangdeindia.jp owns a copyright in the selection, coordination, arrangement and enhancement of such content, as well as in the content original to it. Subscriber may not modify, publish, transmit, participate in the transfer or sale, create derivative works, or in any way exploit, any of the content, in whole or in part. Subscriber may download copyrighted material for Subscriber's personal use only.

Sponsored Links

Advertise Your Business to Indians in Japan
Sell you product, offer your services to Indians living in Japan. We offer pages to businesses in English & Japanese on Rang DE INDIA web portal. Include video presentation and lot more. Starts @ ¥ 46500 for 1 year. Call 03.5875.0780 for details.

Japanese English Translation
Affordable translation services in English and Japanese. Visa document, Tax papers, Marriage certificate, Legal Papers, General, website content, Sub-Titling. We offer Local translation @ offshore price.

India Facebook Page Japan
India Facebook page in Japan is an excellent way to stay connected with the Indians. Learn about the upcoming events in Tokyo and other cities and much more. Visit India Facebook page today